Sign up to save your podcasts
Or
Share Pamrevlumab and idiopathic pulmonary fibrosis
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Pamrevlumab and idiopathic pulmonary fibrosis
Dr. Luca Richeldi discusses a trial looking at pamrevlumab, an anti-connective tissue growth factor therapy for the treatment of idiopathic pulmonary fibrosi
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
View all episodes
By The Lancet Group
5
11 ratings
Dr. Luca Richeldi discusses a trial looking at pamrevlumab, an anti-connective tissue growth factor therapy for the treatment of idiopathic pulmonary fibrosi
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
More shows like The Lancet Respiratory Medicine in conversation with
View all
JAMA Editors' Summary
129 Listeners
History Extra podcast
3,189 Listeners
This Week in Virology
2,052 Listeners
Thorax Podcast
3 Listeners
NEJM This Week
324 Listeners
Out of the Blue: An AJRCCM Podcast
34 Listeners
ERS Publications Podcasts
4 Listeners
ATS Breathe Easy
37 Listeners
JAMA Clinical Reviews
493 Listeners
The Daily
111,785 Listeners
Core IM | Internal Medicine Podcast
1,090 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
349 Listeners
The Lancet Voice
23 Listeners
The Lancet Child & Adolescent Health in conversation with
0 Listeners
The Lancet Digital Health in conversation with
0 Listeners
SmartLess
57,990 Listeners
The Lancet Global Health in conversation with
2 Listeners
The Lancet Oncology in conversation with
1 Listeners
The Lancet Psychiatry in conversation with
0 Listeners
The Rest Is History
12,918 Listeners
The Lancet in conversation with
1 Listeners
The Lancet Haematology in conversation with
0 Listeners
The Lancet Gastroenterology & Hepatology in conversation with
0 Listeners
The Lancet Diabetes & Endocrinology in conversation with
1 Listeners
The Lancet Infectious Diseases in conversation with
0 Listeners
The Lancet Healthy Longevity in conversation with
0 Listeners
The Lancet Public Health in conversation with
1 Listeners
The Lancet Microbe in conversation with
0 Listeners
In conversation with...
0 Listeners
eBioMedicine in conversation with
0 Listeners
eClinicalMedicine in conversation with
0 Listeners
The Lancet Rheumatology in conversation with
0 Listeners
The Lancet Regional Health in conversation with
0 Listeners